appScorecard
Performance
LowHasn't fared well - amongst the low performers
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
LowProfitability and efficiency haven't been upto the mark
Entry point
AvgThe stock is not in the overbought zone
Red flags
AvgThe stock has a moderate number of red flags
How to use scorecard? Learn more
News & Opinions
Transgene Biotek reports consolidated net loss of Rs 2.60 crore in the September 2021 quarter
3 years ago•Business Standard
Transgene Biotek reports consolidated net loss of Rs 2.61 crore in the June 2021 quarter
3 years ago•Business Standard
Transgene Biotek reports consolidated net loss of Rs 2.61 crore in the March 2021 quarter
3 years ago•Business Standard
Transgene Biotek reports consolidated net loss of Rs 2.52 crore in the December 2020 quarter
3 years ago•Business Standard
BRIEF-Transgene Biotek Says Board Approves Licensing Of TrabiORAL To GVK Bio - Investing.com India
4 years ago•Investing.com